Cargando…
Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice
PURPOSE: Non-bismuth concomitant quadruple therapy is commonly administered in Taiwan, achieving an acceptable efficacy as a first-line anti-Helicobacter pylori treatment. This study compared the eradication rates between esomeprazole- and lansoprazole-based non-bismuth concomitant quadruple therapy...
Autores principales: | Hung, Kuo-Tung, Yang, Shih-Cheng, Wu, Cheng-Kun, Wang, Hsing-Ming, Yao, Chih-Chien, Liang, Chih-Ming, Tai, Wei-Chen, Wu, Keng-Liang, Kuo, Yuan-Hung, Lee, Chen-Hsiang, Chuah, Seng-Kee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007608/ https://www.ncbi.nlm.nih.gov/pubmed/33790594 http://dx.doi.org/10.2147/IDR.S304711 |
Ejemplares similares
-
A comparison between dexlansoprazole modified release–based and lansoprazole-based nonbismuth quadruple (concomitant) therapy for first-line Helicobacter pylori eradication: a prospective randomized trial
por: Tai, Wei-Chen, et al.
Publicado: (2019) -
The efficacies of non-bismuth containing quadruple therapies in the treatment of first-line anti-Helicobacter pylori across 4-year time interval with changing antibiotics resistance
por: Huang, Tzu-Hsin, et al.
Publicado: (2021) -
Evaluation of safety and pharmacokinetics of bismuth‐containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication
por: Huh, Ki Young, et al.
Publicado: (2021) -
Efficacy of a 14-day quadruple-therapy regimen for third-line Helicobacter pylori eradication
por: Huang, Hsiang Tso, et al.
Publicado: (2018) -
Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori
por: Gisbert, Javier P, et al.
Publicado: (2012)